Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells

Background Tumor resistance is a frequent cause of therapy failure and remains a major challenge for the long-term management of colorectal cancer (CRC). The aim of this study was to determine the implication of the tight junctional protein claudin 1 (CLDN1) in the acquired resistance to chemotherap...

Full description

Saved in:

Bibliographic Details
Published in:	Cell & bioscience Vol. 13; no. 1; pp. 72 - 17
Main Authors:	Cherradi, Sara, Garambois, Véronique, Marines, Johanna, Andrade, Augusto Faria, Fauvre, Alexandra, Morand, Olivia, Fargal, Manon, Mancouri, Ferial, Ayrolles-Torro, Adeline, Vezzo-Vié, Nadia, Jarlier, Marta, Loussaint, Gerald, Huvelle, Steve, Joubert, Nicolas, Mazard, Thibault, Gongora, Céline, Pourquier, Philippe, Boissière-Michot, Florence, Rio, Maguy Del
Format:	Journal Article
Language:	English
Published:	London BioMed Central 11.04.2023 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	ADC Analysis Animal models Antibodies Antimitotic agents Antineoplastic agents Apoptosis Biological products Biomedical and Life Sciences Cancer Cancer therapies Cell Biology Cell culture Chemoresistance Chemotherapy CLDN1 Clinical trials Colorectal cancer Colorectal carcinoma Flow cytometry Immunofluorescence Immunohistochemistry Kinases Life Sciences Liver Medical prognosis Membranes Metastases Metastasis Microbiology Mutation Neurobiology One-two punch Oxaliplatin Proteins Proteomics Resistance RNA sequencing Scientific equipment and supplies industry Stem Cells Western blotting Wnt protein β-Catenin France United States Denmark ADC Resistance Chemotherapy Biomarker One-two punch Colorectal cancer CLDN1
ISSN:	2045-3701, 2045-3701
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!